NasdaqGS - Delayed Quote • USD
Xilio Therapeutics, Inc. (XLO)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 7:29 PM EDT
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Rene Russo BCPS, Pharm.D. | President, CEO & Director | 888.49k | -- | 1975 |
| Mr. Kevin M. Brennan | Senior VP of Finance & Accounting | -- | -- | 1970 |
| Mr. Christopher Frankenfield | Chief Operating Officer | -- | -- | -- |
| Dr. Uli Bialucha Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Julissa Viana | Vice President of Corporate Communications | -- | -- | -- |
| Ms. Stacey J. Davis | Chief Business Officer | -- | -- | -- |
| Dr. Katarina Luptakova M.D. | Chief Medical Officer | -- | -- | -- |
| Dr. Scott Coleman Ph.D. | Chief Development Officer | -- | -- | -- |
Xilio Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 73
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Xilio Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 05, 2024SC 13G: Tender Offer/Acquisition ReportsSee Full Filing
- Apr 01, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 28, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 19, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 03, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Apr 01, 2024
Xilio Therapeutics, Inc. Earnings Call
Related Tickers
INAB IN8bio, Inc.
1.0500
+5.00%
AVTX Avalo Therapeutics, Inc.
12.01
-11.82%
ANVS Annovis Bio, Inc.
9.85
+9.57%
ELYM Eliem Therapeutics, Inc.
4.1800
-5.64%
NKGN NKGen Biotech, Inc.
0.8600
-16.50%
ACRV Acrivon Therapeutics, Inc.
10.54
+1.93%
TCBP TC Biopharm (Holdings) Plc
1.4200
+5.19%
ABIO ARCA biopharma, Inc.
3.2500
+1.25%
BDRX Biodexa Pharmaceuticals Plc
0.8201
-5.63%
CADL Candel Therapeutics, Inc.
5.46
+0.37%